A placebo-controlled, double blind study on the effect of a dopamine antagonist (Haloperidol??) on appetitive sexual conditioning in healthy female volunteers

• Conditions: seksuele stoornissen; female sexual arousal disorder

• Registration Number: NL-OMON31192
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 128

Inclusion Criteria

female, heterosexual, no sexual complaints for at least one year, and sexually active including intercourse

Exclusion Criteria

- Age < 18 or > 45 years
- BMI < 19
- Homosexual orientation (because of the *male* neutral stimuli)
- Pregnancy or lactation
- A diagnosis of affective, psychotic or substance related disorder according to DSM-IV-TR
- Having undergone a hysterectomy or prolapse surgery
- Using medication that may affect sexual response. To determine possible sexual side-effects the *Farmacotherapeutisch kompas* 2007 will be used.
- Current use of psycho-pharmacological medication, or recent use (less than 4 weeks before participation) of such medication
- Disorders of the genitals that may influence the sexual response or the measurement of the response
- Using drugs or medication that may interfere with haloperidol (for example alcohol, or medication that influences the central nervous system).
- A medical, and/or psychiatric illness or disorder, or a medical, and/or psychiatric history that indicates a risk in using haloperidol (for example cardiac arrhythmia, parkinson, depression, epilepsy, thyroid disorders).
- Use of alcohol or drugs 24 hours preceding participation in the experimental session

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Genital and subjective sexual responses to the conditional stimuli.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Skin Conductance. To determine ANS arousal to the CSs and the US, skin<br /><br>conductance response (SCR) will be measured continuously during the<br /><br>pre-conditioning, conditioning, and post-conditioning phases. Also, to provide<br /><br>evidence of drug *bioactivity* blood pressure will be measured before, and<br /><br>3-hours after, medication administration. </p><br>